Liposomal prostaglandin E1 in acute respiratory distress syndrome: A placebo-controlled, randomized, double-blind, multicenter clinical trial

Critical Care Medicine

Volumn 24, Issue 1 SUPPL., 1996, Pages 10-15

  Abraham, Edward ^a,e   Park, Youn C ^b   Covington, Paul ^c   Conrad, Steven A ^d   Schwartz, Michael ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Liposome Company Incorporated   (United States)

^c Pharmaceutical Product Development   (United States)

^d LOUISIANA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Adult respiratory distress syndrome; Critical illness; Hemodynamics; Liposomes; Lung compliance; Lung injury; Lungs; Neutrophils; Prostaglandin E1; Pulmonary emergencies

Indexed keywords

LIPOPROSTAGLANDIN E1; LIPOSOME; PLACEBO; PROSTAGLANDIN E1; ANTITHROMBOCYTIC AGENT; DRUG CARRIER;

ADULT; AGED; AGITATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODYNAMICS; HUMAN; HYPOTENSION; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; LUNG COMPLIANCE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS SYNDROME; SIDE EFFECT; SURVIVAL; ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY;

ADULT; ALPROSTADIL; DOUBLE-BLIND METHOD; DRUG CARRIERS; FEMALE; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 0029664979     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199601000-00005     Document Type: Article

References (13)

1. Repine JE: Scientific perspectives on adult respiratory distress syndrome. Lancet 1992; 339:466-469
2. Bernard GR, Artigas A, Brigham KL, et al: The American-European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149:818-824
3. Milberg JA, Davis DR, Steinberg KP, et al: Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA 1995; 273:306-309
4. 1 inhibits neutrophil adherence and neutrophil-mediated injury to cultured endothelial cells. Am Rev Respir Dis 1988; 138: 915-920
5. 1 in decreasing in vivo platelet deposition on human lesion sites after intravenous and intraarterial application. Thromb Res 1988; 50:749-755
6. Priebe HJ: Efficacy of vasodilator therapy in a canine model of acute pulmonary hypertension. Am J Physiol 1988; 255:H1232-H1239
7. 1 and survival in patients with the respiratory distress syndrome: A prospective trial. Ann Surg 1986; 203:371-378
8. 1 in patients with the adult respiratory distress syndrome. Chest 1989; 96:114-119
9. Eierman DF, Yagami M, Erme SM, et al: Endogenously opsonized particles divert prostanoid action from lethal to protective in models of experimental endotoxemia. Proc Natl Acad Sci USA 1995; 92:2815-2819
10. 1 posttreatment decreases IL-1α-induced neutrophil accumulation and lung leak in rats. J Appl Physiol 1994; 76:151-157
11. 1 in a canine thrombolysis model. J Am Coll Cardiol 1994; 24:1382-1390
12. Murray JF, Matthay MA, Luce JM, et al: An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988; 138:720-723
13. Suchyta MR, Clemmer TP, Orme JF, et al: Increased survival of ARDS patients with severe hypoxemia (ECMO criteria). Chest 1991; 99:951-955